Back to Search
Start Over
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
- Source :
-
Molecular neurobiology [Mol Neurobiol] 2016 Jul; Vol. 53 (5), pp. 3326-3337. Date of Electronic Publication: 2015 Jun 17. - Publication Year :
- 2016
-
Abstract
- Microglia-associated inflammatory processes have been strongly implicated in the development and progression of Parkinson's disease (PD). Specifically, microglia are activated in response to lipopolysaccharide (LPS) and become chronic source of cytokines and reactive oxygen species (ROS) production. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex is responsible for extracellular as well as intracellular production of ROS by microglia and its expression is upregulated in PD. Therefore, targeting NADPH oxidase complex activation using an NADPH oxidase inhibitor, i.e., apocyanin seems to be an effective approach. The aim of present study was to investigate the neuroprotective effects of apocyanin in a LPS-induced PD model. LPS (5 μg) was injected intranigral and apocyanin was administered daily at a dose of 10 mg/kg b.wt (i.p.) during the experiment. LPS when injected into the substantia nigra (SN) reproduced the characteristic hallmark features of PD in rats. It elicited an inflammatory response characterized by glial cell activation (Iba-1, GFAP). Furthermore, LPS upregulated the gene expression of nuclear factor-κB (NFκB), iNOS, and gp91PHOX and resulted in an elevated total ROS production as well as NADPH oxidase activity. Subsequently, this resulted in dopaminergic loss as depicted by decreased tyrosine hydroxylase (TH) expression with substantial loss in neurotransmitter dopamine and its metabolites, whereas treatment with apocyanin significantly reduced the number of glial fibrillary acidic protein (GFAP) and Iba-1-positive cells in LPS-treated animals. It also mitigated microglial activation-induced inflammatory response and elevation in NADPH oxidase activity, thus reducing the extracellular as well as intracellular ROS production. The present study indicated that targeting NADPH oxidase can inhibit microglial activation and reduce a broad spectrum of toxic factors generation (i.e., cytokines, ROS, and reactive nitrogen species [RNS]), thus offering a hope in halting the progression of PD.
- Subjects :
- 3,4-Dihydroxyphenylacetic Acid metabolism
Acetophenones pharmacology
Animals
Cytokines genetics
Cytokines metabolism
Disease Models, Animal
Enzyme Activation drug effects
Enzyme Inhibitors pharmacology
Enzyme Inhibitors therapeutic use
Homovanillic Acid metabolism
Inflammation Mediators metabolism
Lipid Peroxidation drug effects
Lipopolysaccharides
Male
Mesencephalon pathology
NADPH Oxidases metabolism
Nerve Degeneration pathology
Nitric Oxide metabolism
Nitric Oxide Synthase Type II metabolism
RNA, Messenger genetics
RNA, Messenger metabolism
Rats, Sprague-Dawley
Reactive Oxygen Species metabolism
Tyrosine 3-Monooxygenase metabolism
Acetophenones therapeutic use
Dopaminergic Neurons pathology
Microglia enzymology
NADPH Oxidases antagonists & inhibitors
Nerve Degeneration drug therapy
Nerve Degeneration prevention & control
Parkinson Disease drug therapy
Parkinson Disease pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1559-1182
- Volume :
- 53
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Molecular neurobiology
- Publication Type :
- Academic Journal
- Accession number :
- 26081143
- Full Text :
- https://doi.org/10.1007/s12035-015-9267-2